Welcome to our dedicated page for VRAY news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on VRAY stock.
ViewRay, Inc. (Nasdaq: VRAY) is a trailblazer in the field of MRI-guided adaptive radiotherapy. The company designs, manufactures, and markets the MRIdian® radiation therapy system, an innovative solution aimed at addressing the key limitations of conventional external-beam radiation therapy technologies. Using cutting-edge MRI-based technology, the MRIdian system provides real-time imaging that precisely distinguishes the targeted tumor from surrounding soft tissue and critical organs during radiation treatment.
One of the standout features of the MRIdian system is its capability to record the level of radiation exposure the tumor receives and adapt the treatment prescription as needed. This adaptive approach enhances the safety and efficacy of radiation therapy, which ViewRay believes will lead to better patient outcomes.
ViewRay has established itself as a visionary in the medical field, dedicated to providing doctors with advanced tools to improve cancer treatment through radiation therapy. The company prides itself on its entrepreneurial spirit and unwavering commitment to innovation and excellence.
Among its recent achievements, ViewRay announced that the VA Oklahoma City Healthcare System has selected the MRIdian system to expand its radiation therapy services. This marks the first cancer center in Oklahoma to offer Veterans access to MRIdian's advanced MRI-guided radiation therapy. The system will enable precision treatment for various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic disease.
The Veterans Health Administration, the largest integrated healthcare system in America, is actively incorporating MRIdian technology across multiple VA medical centers. This expansion highlights the growing recognition of MRIdian's short-course non-invasive therapy, which promises fewer side effects and improved quality of life for patients.
To date, over 31,000 patients worldwide have been treated using MRIdian systems, with 62 installations in hospitals across the globe. These systems are employed to treat a diverse range of solid tumors and are subjects of numerous ongoing research studies. The MRIdian system has been featured in hundreds of peer-reviewed publications and scientific presentations, underscoring its clinical significance and impact.
For a list of treatment centers utilizing MRIdian technology, visit ViewRay's website.
ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023. Domestic callers can join at (888) 886-7786 using confirmation number 56031524. A live webcast will also be available on ViewRay's investor relations page. The MRIdian® MR-Guided Radiation Therapy System, designed with high-definition MR imaging, addresses challenges in advanced radiation oncology, such as beam distortion and skin toxicity. This innovative technology differentiates itself from conventional MR systems used in diagnostic radiology.
ViewRay (NASDAQ: VRAY) announced that the Czech Ministry of Health has approved the acquisition of its MRIdian system, making it the first and only facility to provide advanced MRI-guided radiation therapy in the Czech Republic at the Military University Hospital Prague. This purchase, partially funded by the REACT-EU financial instrument, enhances cancer treatment options with precision technology that includes real-time tissue tracking and automatic beam control. Over 29,000 patients have already benefited from MRIdian systems, which are installed in 57 hospitals worldwide.
FAQ
What does ViewRay, Inc. specialize in?
What is the MRIdian® system?
What recent achievement has ViewRay announced?
How many patients have been treated with the MRIdian system?
How many MRIdian systems are currently installed worldwide?
What types of cancer can be treated with MRIdian?
Why is MRIdian considered advanced in radiation therapy?
What are some common side effects of radiation therapy with MRIdian?
Is MRIdian suitable for all patients?
Where can I find more information about MRIdian treatment centers?
